Cravath partner Benjamin Gruenstein participated in “Compliance & Ethics Essentials 2025,” a program presented by the Practising Law Institute from June 26‑27 in New York. Ben co‑led a presentation entitled “Legal Ethics for Compliance Lawyers and Compliance Officers,” which explored the ethical obligations of in‑house lawyers and compliance professionals, including how companies should structure their ethics and compliance programs within their organization, how and when to maintain attorney‑client privilege during investigations and what to do when compliance officers and general counsels play competing roles in giving compliance advice.

On July 1, 2025, Cravath partner Brittany L. Sukiennik was named a 2025 “Rising Star” by the New York Law Journal. The award recognizes “the region’s most promising lawyers.” Winners will be featured online and honored at an event in September.

On June 30, 2025, Cravath partner Korey Fevzi was named to Financial News’ “Fifty Most Influential Lawyers” list for 2025, which recognizes “senior lawyers in private practice in M&A, capital markets, financial regulation, and private markets across Europe, including the UK.” Honorees were selected through “extensive research,” considering candidates’ “influence in their respective fields, leadership within the sector, performance over the past year, and their potential to shape their businesses and/or the industry in the years ahead.”

On July 1, 2025, Cravath prepared a memo for its clients entitled “Structuring Share Repurchases: Rule 10b‑18 and Rule 10b5‑1 Applied to Open‑Market Share Repurchase Programs, Accelerated Share Repurchase Transactions and Enhanced Open‑Market Share Repurchase Transactions.”

Cravath represented Circle Internet Financial, LLC on SEC regulatory matters concerning the non‑applicability of securities laws to payment stablecoins, concurrent with Circle Internet Group Inc.’s initial public offering.

Lisa Siders is General Counsel at Avon Products, Inc. and the Chief Transformation Officer at Avon International. In the inaugural “Where Are They Now?” episode of On Tax, Lisa returns to talk with Cravath partner and host Len Teti about her career since she last appeared on the show as Vice President of Tax at Natura &Co in Season 1 (listen to that episode here). They also discuss the qualities that enable tax attorneys to excel across a variety of (sometimes unexpected) functions and reflect on the importance of building trust among clients and colleagues.

Cravath represented the initial purchasers in connection with the $650 million 144A/Reg. S high‑yield senior notes offering of Compass Minerals International, Inc., a leading provider of essential minerals. The transaction closed on June 16, 2025.

On June 27, 2025, Cravath partners Michael A. Paskin, George E. Zobitz, Paul H. Zumbro, Jelena McWilliams, Lauren A. Moskowitz, Omid H. Nasab and Michael J. Zaken were named to Lawdragon’s 2025 list of “500 Leading Global Bankruptcy and Restructuring Lawyers” in recognition of their work advising clients during “crises that imperil their existence.” The list honors “lawyers who tune out the noise and find the path forward through tough negotiation, litigation, or complex financial arrangements,” and celebrates their ability to “help organizations move forward.”

On June 26, 2025, the Foreign Policy Association (“FPA”) presented Cravath Presiding Partner Faiza J. Saeed with the organization’s highest honor, the Foreign Policy Association Medal, at its annual Corporate Dinner held in New York, alongside Carlos Cuerpo, Spain’s Minister of Economy, Trade and Business, and Peter Young, CEO and President of Young and Partners.

On June 20, 2025, Cravath partner Sharonmoyee Goswami participated in the 2025 SABA North American Annual Conference, an annual gathering of South Asian attorneys, judges, general counsel, law firm leaders and public officials, which was hosted by the South Asian Bar Association of North America from June 19‑22 in Denver, Colorado. Sharon spoke on a panel entitled “Mastering Expert Testimony in Patent Trials: Strategies for Persuasion and Clarity Before a Jury,” where she also demonstrated a mock direct and redirect examination of a technical expert.

Cravath partner Arvind Ravichandran was featured as a guest on the June 27, 2025 episode of Slaughter and May’s podcast, “Tax News.” In the interview, Arvind discussed key tax aspects in the “One Big Beautiful Bill” that is currently working its way through Congress, including expected domestic and international tax changes, potential impacts on markets and key open items as the legislation moves towards passage.

Cravath represented the underwriters in connection with the $400 million fixed‑rate reset subordinated notes offering of Fidelis Insurance Holdings Limited, a global specialty insurer that leverages strategic partnerships to offer innovative and tailored insurance solutions. The transaction closed on June 13, 2025.

Cravath partners Brittany L. Sukiennik and Benjamin G. Joseloff participated in the 30th Annual Stanford Directors’ College, which was held from June 23‑25, 2025, at Stanford Law School. The program addressed a broad range of problems that confront modern boards, including the board’s role in setting business strategy, CEO succession, techniques for controlling legal liability, challenges posed by activist investors, boardroom dynamics and contemporary challenges, including the state of the macroeconomy, the politicization of the corporation and emerging ransomware and cybersecurity threats.

Cravath partner Nicholas A. Dorsey served as the co‑editor of the 2025 edition of the Chambers Acquisition Finance Guide, which is part of the publisher’s Global Practice Guide series. Nick also co‑authored, along with Cravath partners Ryan J. Patrone, Kelly M. Smercina and Margaret R. M. Rallings, the U.S. chapter of the guide.

On June 23, 2025, Illumina, Inc. (“Illumina”) announced it has entered into a definitive agreement with Standard BioTools under which Illumina will acquire SomaLogic, a leader in data‑driven proteomics technology, and other specified assets for $350 million in cash payable at closing, subject to customary adjustments, plus up to $75 million in near-term performance‑based milestones and performance‑based royalties. Cravath is representing Illumina in connection with the transaction.

Cravath represented ODDITY Tech in connection with the $600 million Rule 144A exchangeable senior notes offering by Oddity Finance LLC, guaranteed by ODDITY Tech Ltd. and IM Pro Makeup NY L.P. Oddity Finance LLC is a wholly owned, indirect subsidiary of ODDITY Tech, a consumer technology company building digital‑first brands for the beauty and wellness industries worldwide. In addition, Cravath advised Oddity Finance LLC in connection with capped call transactions entered into in connection with the offering. The transaction closed on June 12, 2025.

Cravath represented Toll Brothers Finance Corp. in connection with its $500 million registered senior notes offering, fully guaranteed by Toll Brothers, Inc. and certain of its subsidiaries. Toll Brothers Finance Corp. is an indirect wholly owned subsidiary of Toll Brothers, Inc., which designs, builds, markets, sells and arranges financing for an array of luxury residential homes and communities. The transaction closed on June 10, 2025.

Cravath represented Burlington Northern Santa Fe, LLC in connection with its $900 million registered notes offering. Burlington Northern Santa Fe, LLC is a holding company engaged primarily in railroad transportation through its ownership of its principal operating subsidiary, BNSF Railway Company. Burlington Northern Santa Fe, LLC is owned by Berkshire Hathaway. The transaction closed on June 6, 2025.

Cravath has elected the following new partners, who will become members of the Firm on July 1, 2025:

Cravath represented the administrative agent, joint lead arranger and joint bookrunner in connection with a $4.5 billion revolving credit facility made available to Cencora, Inc., a leading global pharmaceutical sourcing and distribution services company, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The transaction closed on June 4, 2025.